The characteristic substances Doxycycline
Derived tetracycline derived synthetically from auxitetratziklina. Doxycycline is a light yellow crystalline powder. Doxycycline monohydrate is very slightly soluble in water, molecular weight 462.46. Doxycycline hyclate (gemiètanolat hydrochloride hemihydrate) is soluble in water.
Drugs, the anti wide spectrum, bacteriostatic.
Ingibiruet fusion protein in the microbial cell, disrupting communication aminoacyl-tRNA with the 30S subjedinica ribosomalna membranes.
Once inside almost completely absorbed (90-100%), eating an insignificant effect on the skin has a high solubility in lipids and low affinity binding of calcium. Stable plasma. When administered orally 200 mg of doxycycline averages farmakokineticeskih parameters were as follows:-3.61 Cmax µg/ml Tmax is 2.60 h; constant speed off 0.049-h-1, T1/2-16.33 hours the plasma protein binds 80-92%. Penetrate most body fluids and tissue in bile, the secret of the paranasal sinuses, plevralny vpot, sinovialnuu astiticescuu fluid, fluid and gingival sulci. The apparent volume of distribution is 52.6-134 l. accumulates in bones, teeth, liver, spleen, prostate gland, creates therapeutic concentrations in the tissues of the eye. Penetrates through the placenta and is found in the body of the fetus. Bad penetrates into the spinal marrow fluid (10-20% from the level in the plasma). 20-60% of the dose excreted intestinal remaining 35-60% of kidneys (20-50% in unmodified form). Normal renal function (creatinine clearance is approximately 75 ml/min) excretion through the kidneys is 40% for 72 h T1/2 does not change if any of the kidneys, as in patients with impaired renal azotemia or favouring by deducing is gastro-intestinal secretion. With severe chronic renal insufficiency (creatinine clearance of approximately 10 mL/min) excretion through the kidneys may constitute 1-5% for 72 h. Hemodialysis does not affect the T1/2 of doxycycline from the plasma. T1/2 After a single admission is 6:00 pm When re-introductions possible cumulation. Doxycycline forms insoluble complexes with calcium in the bones and teeth.
Active against protozoa (malaria Plasmodium, Amoeba, etc.). The most susceptible Haemophilus influenzae (91-96%) and intracellular pathogens. There are cross-resistant to other tetracycline, as well as to penitsillinam. Highly effective in the treatment of pneumonia and acute bronchitis mycoplasmal etiology. If there is evidence to antimicrobial therapy for acute chronic bronchitis, incl. in the face of a bronchial asthma, is used as first-line drug in patients up to 65 years without opportunistic diseases (such aggravation more often associated with Haemophilus influenzae). Is having a pronounced effect in acute pulmonary infection (usually staph etiology) in patients with cystic fibrosis, Reiter’s syndrome, caused by clamydia, dermal leishmaniasis. The most effective in the treatment of granulocytic ehrlichiosis. Older patients shows effect of empirical therapy of acute prostatitises, and urinary tract infections caused by the bacteria Escherichia. In ophthalmic practice used for the treatment of genital keratitov stafilo-, strepto-and pneumococcal etiology. Coupled with vsokoeffectiven quinine in the treatment of malaria. Block matrix Metalloproteinases (enzymes, which catalyse the degradation of collagen and protheoglicanov) in cartilage, reduces losses in deforming osteoartroze (experimental data).
Substance use Doxycycline
Infections caused by susceptible, including intracellular infections: fever Ku, Rocky Mountain spotted fever, typhus (including curricular, breakout), brucellosis, yersiniosis, bacillary and amoebic dysentery, tularaemia, cholera, Lyme disease (stage I), aktinomikoz, malaria; in a combination therapy is leptospirosis, trachoma, psittacosis, granulocyte erlihioz; diseases of ENT organs and divisions lower respiratory tract infections (sinusitis, otitis, tonsillitis, acute bronchitis, exacerbation of chronic bronchitis, pneumonia, Pleurisy), infection